Thyrocare Share Price: Q3 Results ne machaya dhamal! Profit **47%** bhaga, Revenue **18%** up!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Thyrocare Share Price: Q3 Results ne machaya dhamal! Profit **47%** bhaga, Revenue **18%** up!
Overview

Yaar, Thyrocare ke investors ke liye khush khabar hai! Company ne Q3 mein kamaal kar diya hai. Revenue **18%** bhaga kar **₹196 Crore** tak pahunch gaya aur Profit toh seedha **47%** upar chala gaya!

Asli numbers kya bol rahe hain?

Toh hua yun ki Thyrocare Technologies ne Q3 FY26 mein apne results announce kiye hain aur numbers ekdum zabardast hain.

  • Consolidated Revenue 18% YoY growth ke saath ₹196 Crore ho gaya hai.
  • Stand-alone Revenue bhi 20% badh kar ₹183 Crore pahunch gaya.
  • Sabse mast baat yeh hai ki Profit After Tax (PAT) mein 47% ka zabardast jump aaya hai.
  • EPS bhi 39% badha hai, jo ab ₹1.64 ho gaya hai.
  • EBITDA margins bhi improve hue hain. Consolidated mein yeh 32% (jo 26% up hai) aur stand-alone mein 34% (jo 31% up hai) rahe.
  • Total tests processed bhi 22% badh kar 49.6 million ho gaye.

Kuch exceptional items bhi the, lagbhag ₹6 Crore ke, jo mainly provisions aur bonus ke liye hain, toh yeh sab operational costs nahi hain.

Growth ka engine kaise chala?

Company ne sirf revenue hi nahi badhaya, balki profit ko revenue se bhi zyada tezi se badhaya hai, jo ki cost management aur operational efficiency dikhata hai. EBITDA margins mein bhi acchi improvement dikh rahi hai. Aur log sample de rahe hain, test badh rahe hain, matlab business sahi chal raha hai.

Aage kya plan hai? (The Grill)

Management ka kehna hai ki woh mid-teens (around 15-16%) ka consolidated growth target kar rahe hain. Franchisee business 12-15% aur partnerships usse bhi zyada grow ho sakte hain. Lekin haan, woh yeh bhi keh rahe hain ki nayi cheezein launch karne aur infrastructure mein invest karne ki wajah se ho sakta hai ki margin expansion thoda slow ho jaye. Matlab profit toh badhega, par percentage mein shayad utna zyada na badhe jitna abhi dikh raha hai.

Nayi strategies aur expansion

Thyrocare ab brand ko aur strong bana raha hai. Bollywood actress Madhuri Dixit ko brand ambassador banaya gaya hai, jisse trust aur reach badhegi. Naye leaders bhi aa gaye hain - Dr. Ramesh Kinha COO aur Rajdeep Panwar CCO bane hain. Operations aur sales strategy ko boost milega. Domestic level par bhi expansion ho raha hai, jaise Davangere aur Mandi mein naye labs khule hain. Aur international level par, Tanzania mein toh revenue 140% badh gaya hai aur woh log 12-18 mahine mein breakeven par aa jayenge.

Risks aur Outlook

Sabse bada risk toh yeh hai ki growth ke liye jo investments kar rahe hain, woh shayad margins ko zyada badhne na de. Outlook positive hai aur double-digit growth ki umeed hai, par yeh dekhna hoga ki yeh investments kitne effective rehte hain. Company quality par focus kar rahi hai (100% NABL accredited) aur nayi tests bhi add kar rahi hai. Overall, domestic aur international dono jagah expansion dikh raha hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.